Comparative clinical trial of ziprasidone and risperidone in the treatment of male schizophrenia

Objective To investigate the efficacy and safety of ziprasidone in the treatment of schizophrenia.Methods Randomly,clinical controlled divided the 76 cases of patients with schizophrenia into the ziprasidone group(38 cases) and the risperidone group(38 cases).Two groups received 8weeks treatment with ziprasidone(80~160 mg·d-1) or risperidone(3~6 mg·d-1).The efficacy was evaluated with the change in total score of positive and negative symptom scale(PANSS).The safety was evaluated with sumptom scale(TESS),the results of laboratory examintion.Results At the end of treatment,both the score of these two groups are significantly lower(P0.01),the total effective of ziprasidone group was 86.84% and risperidone group was 89.47%.No significant efficacy differences between the two groups(P0.05).The incidence adverse events of ziprasidone and risperidone were 42.11% and 47.37%,also no great difference of overall adverse events,and clinical manifestations are similar(P0.05),the adverse events are mild.Conclusion Ziprasidone is an effective and safe drug in treatment of schizophrenia.